Table 1.
Demographic and clinical characteristic of people living with HIV/AIDS by cART status in the ClinSurv HIV Cohort, Germany 2001–2011
|
Characteristic |
Non-cART |
cART* |
Total |
|---|---|---|---|
| N = 2,467 (21.1%) | N = 9,226 (78.9%) | N = 11,693 (100%) | |
| TB patients |
103 (4.2%) |
130 (1.4%) |
233 (2%) |
| Gender |
|
|
|
| Male |
1.994 (80.8%) |
7,394 (80.2%) |
9,388 (80.3%) |
| Female |
473 (19.2%) |
1,831 (19.9%) |
2,304 (19.7%) |
| Age at enrollment, years |
|
|
|
| Median [IQR] |
35 [29–42] |
39 [32–46] |
38 [31–45] |
| ≤38 |
1,468 (59.6%) |
4,338 (47.1%) |
5,806 (49.7%) |
| >38† |
994 (40.4%) |
4,873 (52.9%) |
5,867 (50.3%) |
| Geographical origin |
|
|
|
| Germany |
1,731 (72.1%) |
6,631 (73.0%) |
8,362 (72.8%) |
| Sub-Saharan Africa |
255 (10.6%) |
1,066 (11.7%) |
1,321 (11.5%) |
| HIV-transmission risk group |
|
|
|
| MSM |
1,339 (60.3%) |
4,768 (57.8%) |
6,107 (58.4%) |
| Other |
881 (39.7%) |
3,477 (42.8%) |
4,358 (41.6%) |
| CD4+ cell count at enrollment in the cohort, cells/μl |
|
|
|
| Median [IQR] |
492 [349–663] |
273 [118–453] |
320 [146–508] |
| >200 |
2,054 (89.1%) |
5,467 (61.9%) |
7,521 (67.6%) |
| ≤200† |
251 (10.9%) |
3,362 (38.1%) |
3,613 (32.5%) |
| Viral load at enrollment in the cohort, log10 copies/ml |
|
|
|
| Median [IQR] |
4.2 [3.4 – 4.8] |
4.5 [3.1 – 5.2] |
4.4 [3.3 – 5.7] |
| <5 |
1,769 (72.9%) |
5,845 (68.1%) |
7,614 (70.5%) |
| ≥5† |
446 (20.1%) |
2,737 (31.9%) |
3,183 (29.5%) |
| Calendar year of enrollment |
|
|
|
| 2001 |
147 (5.9%) |
765 (8.2%) |
912 (7.7%) |
| 2002 |
166 (6.7%) |
832 (9.0%) |
998 (8.4%) |
| 2003 |
178 (7.2%) |
839 (10.1%) |
1,017 (8.7%) |
| 2004 |
205 (8.3%) |
928 (10.1%) |
1,133 (9.7%) |
| 2005 |
213 (8.6%) |
908 (9.8%) |
1,121(9.5%) |
| 2006 |
225 (9.1%) |
842 (9.1%) |
1,067 (9.1%) |
| 2007 |
251(10.2%) |
893 (10.6%) |
1,144 (9.8%) |
| 2008 |
217 (8.8%) |
883 (9.5%) |
1,100 (9.4%) |
| 2009 |
249 (10.1%) |
835 (9.1%) |
1,084 (9.3%) |
| 2010 |
278 (11.3%) |
811 (8.8%) |
1,089 (9.3%) |
| 2011 |
338 (13.7%) |
690 (7.5%) |
1,028 (8.8%) |
| Length of follow-up (person-years) |
|
|
|
| Median [IQR] | 1.2 [0.3-2.8] | 3.1 [1.3-5.9] | 2.5 [1.1-5.3] |
cART, combination antiretroviral therapy; TB, tuberculosis; IQR; interquartile range; MSM, men who have sex with men; PWID, person who inject drugs; HPC, high HIV-prevalence countries.
*cART initiated during follow-up at any time prior to TB diagnosis.
†Significantly associated with receiving cART (multivariable logistic regression model including all presented characteristics as independent variables; P < 0.05).